Buscar
Mostrando ítems 1-5 de 5
Artículo
Effectiveness of Fosfomycin for the Treatment of Multidrug-Resistant Escherichia coli Bacteremic Urinary Tract Infections A Randomized Clinical Trial
(Jama Nerwork Open, 2022)
Importance The consumption of broad-spectrum drugs has increased as a consequence of the spread of multidrug-resistant (MDR) Escherichia coli. Finding alternatives for these infections is critical, for which some neglected ...
Artículo
Population pharmacokinetics of piperacillin in non-critically ill patients with bacteremia caused by enterobacteriaceae
(MDPI, 2021-03-25)
This study analyzes the pharmacokinetic variability of piperacillin in non-critically ill patients with Enterobacteriaceae bloodstream infections (EBSI) and explores predicted clinical outcomes and piperacillin-related ...
Artículo
Whole transcription profile of responders to anti-tnf drugs in pediatric inflammatory bowel disease
(MDPI, 2021-01-08)
Background: Up to 30% of patients with pediatric inflammatory bowel disease (IBD) do not respond to anti-Tumor Necrosis Factor (anti-TNF) therapy. The aim of this study was to identify pharmacogenomic markers that predict ...
Artículo
Association between HLA DNA variants and long-term response to anti-TNF drugs in a Spanish pediatric inflammatory bowel disease cohort
(MDPI, 2023-01-16)
The genetic polymorphisms rs2395185 and rs2097432 in HLA genes have been associated with the response to anti-TNF treatment in inflammatory bowel disease (IBD). The aim was to analyze the association between these variants ...
Artículo
Gene signatures of early response to anti-TNF drugs in pediatric inflammatory bowel disease
(MDPI, 2020)
Around a 20–30% of inflammatory bowel disease (IBD) patients are diagnosed before they are 18 years old. Anti-TNF drugs can induce and maintain remission in IBD, however, up to 30% of patients do not respond. The aim of ...